Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 17/20 | 0.84 |
| ▸ | MMP13 | P45452 | 5/20 | 0.73 |
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7108148 | 0.96 | ADAM17 (0.78) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL7107278 | 0.95 | ADAM17 (0.85) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL7108828 | 0.94 | ADAM17 (0.79) | ADAM17MMP13 | |
| SCHEMBL7113461 | 0.92 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL7110719 | 0.90 | ADAM17 (0.79) | ADAM17MMP13 | |
| SCHEMBL7109820 | 0.89 | ADAM17 (0.89) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110992 | 0.89 | ADAM17 (0.72) | ADAM17MMP13 | |
| SCHEMBL7108155 | 0.89 | ADAM17 (0.67) | ADAM17MMP13 | |
| Trifluoroacetic Acid SCHEMBL7110121 | 0.88 | ADAM17 (0.91) | ADAM17MMP13MMP2MMP9 | |
| SCHEMBL7106430 | 0.87 | ADAM17 (1.00) | ADAM17MMP13MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | claimed |
| US-6642255-B2 | Substituted carbocyclic or heterocyclic hydroxamic acid derivatives, e.g., (3R,4S)-N-hydroxy-1-methyl-3-(((4-((2-methyl-4 -quinolinyl)methoxylphenyl)sulfonyl)methyl)-4-piperidinecarboxamide | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087890-A1 | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha | MMP1, MMP8, MMP9 | ADAM17 19/4885MMP13 10/4885MMP2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.